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Abstract: Adenoviruses (Ad) are commonly used both experimentally and clinically, including
oncolytic virotherapy applications. In the clinical area, efficacy is frequently hampered by the high
rates of neutralizing immunity, estimated as high as 90% in some populations that promote vector
clearance and limit bioavailability for tumor targeting following systemic delivery. Active tumor
targeting is also hampered by the ubiquitous nature of the Ad5 receptor, hCAR, as well as the lack of
highly tumor-selective targeting ligands and suitable targeting strategies. Furthermore, significant
off-target interactions between the viral vector and cellular and proteinaceous components of the
bloodstream have been documented that promote uptake into non-target cells and determine
dose-limiting toxicities. Novel strategies are therefore needed to overcome the obstacles that
prevent efficacious Ad deployment for wider clinical applications. The use of less seroprevalent
Ad serotypes, non-human serotypes, capsid pseudotyping, chemical shielding and genetic masking
by heterologous peptide incorporation are all potential strategies to achieve efficient vector escape
from humoral immune recognition. Conversely, selective vector arming with immunostimulatory
agents can be utilized to enhance their oncolytic potential by activation of cancer-specific immune
responses against the malignant tissues. This review presents recent advantages and pitfalls
occurring in the field of adenoviral oncolytic therapies.
Keywords: adenovirus; oncolytic; virotherapy; immune epitope; neutralization; genetic masking;
chimeric vector; pseudotyping; cancer immunotherapy
1. Adenovirus Immunogenicity
1.1. Introduction
Adenoviruses (Ads) are non-enveloped viruses containing a linear double-stranded 34–36 kb
DNA genome within an icosahedral capsid. They belong to the Adenoviridae family. Human Ads
were historically classified into species A–G based on their DNA homology, hemagglutination,
oncogenic and neutralization properties, with species D containing the largest number of different
Ad serotypes (for a comprehensive review, see [1]). Systematic sequence analyses have yielded
detailed information on the evolutionary relationships between different Ad serotypes and enabled
the classification of the 57 human Ad serotypes based on alignment of the main capsid proteins—fiber,
hexon and penton base (Figure 1). Twenty species D Ads have recently been fully sequenced and
found to exhibit great diversity in the hypervariable regions (HVRs) of the capsid proteins [2].
The extensive variability within the species D is suggested to be a result of natural homologous
recombination, a common mechanism responsible for viral genome fitness and diversity due to
selective immune pressure in the human host, which is likely to result in novel variants with altered
tropism and virulence [2].
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Figure 1. Adenovirus particle with the three major antigenic capsid proteins. Penton base, hexon and 
fiber (shown here as monomers) are the main building blocks of the capsid structure, but also contain 
the major immunogenic epitopes (highlighted in colors) that are explained in greater detail in Section 1.3 
of this review. 
Ad viruses are constantly circulating in the human population, with small seasonal fluctuations. 
They are capable of infecting individuals of all ages, although babies and young children are most 
affected due to previous seronegativity. Ad infections commonly result in non-life-threatening 
conditions including mild upper and lower respiratory tract infections, gastroenteritis, cystitis or 
keratoconjunctivitis (Table 1) but can in rare cases produce manifestations with high morbidity and 
mortality such as hepatitis, pneumonia, meningoencephalitis and myocarditis (reviewed in [3]). 
Opportunistic infections are seen in severely immunosuppressed patients and allogeneic stem cell (or 
organ) transplant recipients, in whom the consequences can be fatal due to severe inflammatory host 
responses, cytokine “storms” and extensive immune attacks, as was demonstrated tragically in 1999 
when a young volunteer patient receiving gene therapy for ornithine transcarbamylase deficiency 
died as a result of a cytokine storm following intravascular delivery of a huge dose (3.8 × 1013 viral 
particles) of Ad5 [4]. This case provided a significant low point in the clinical development of Ad as 
a biotherapy, and highlighted the requirement to better understand and refine the dose-limiting 
interactions that limit efficacy and promote toxicity clinically. Disseminated infections are generally 
associated with high liver and kidney toxicity, and may result in multi-organ failure due to high virus 
burden in the blood. Ad infections in immunocompetent and -compromised patients are discussed 
in detail in a recent review by Lion and colleagues [3]. 
Ad was originally isolated from a human adenoid tissue sample in 1953 [5]. The past 60 years 
have provided compelling evidence of the tumor-killing (oncolytic) potential of Ad-based vectors. 
They infect both dividing and non-dividing cells, and can incorporate large transgenes to their 
genome without the risk of integration into the host genome, and are therefore not considered to be 
intrinsically oncogenic (unlike some integrating viral vectors). Due to the generally mild nature of 
the disease manifestation and long clinical history, Ads are widely considered to be safe delivery 
vectors for gene therapy applications. The Ad genome is well-characterized, compact and largely 
permissive for a plethora of genetic modifications. Hence novel vector candidates are continuously 
being assessed for effective and safe future therapeutics. The latest trends in Ad gene therapy have 
included oncolytic Ads (OAds) with a variety of cancer-specificities, tumor vaccines, cancer 
immunotherapies and modulation of immune checkpoint control mechanisms (for reviews on 
oncolytic Ad-based therapies, see [6–9]). 
Ad serotype 5 (Ad5) has been the most commonly used delivery vector for experimental and 
clinical purposes, and comprises the majority of gene therapy trials worldwide [10]. However, its wider 
use is severely limited by high levels of pre-existing humoral immunity in the general population, 
estimated to be >90% in certain geographical locations such as in sub-Saharan Africa [11–13]. 
Neutralizing antibodies (nAbs) directed against the primary antigenic epitopes in the three major 
Figure 1. Adenovirus particle with the three major antigenic capsid proteins. Penton base, hexon
and fiber (shown here as monomers) are the main building blocks of the capsid structure, but also
contain the major immunogenic epitopes (highlighted in colors) that are explained in greater detail in
Section 1.3 of this review.
Ad viruses are constantly circulating in the human population, with small seasonal fluctuations.
They are capable of infecting individuals of all ages, although babies and young children are most
affected due to previous seronegativity. Ad infections commonly result in non-life-threatening
conditions including mild upper and lower respiratory tract infections, gastroenteritis, cystitis or
keratoconjunctivitis (Table 1) but can in rare cases produce manifestations with high morbidity
and mortality such as hepatitis, pneumonia, meningoencephalitis and myocarditis (reviewed in [3]).
Opportunistic infections are seen in severely immunosuppressed patients and allogeneic stem cell (or
organ) transplant recipients, in whom the consequences can be fatal due to severe inflammatory host
responses, cytokine “storms” and extensive immune attacks, as was demonstrated tragically in 1999
when a young volunteer patient receiving gene therapy for ornithine transcarbamylase deficiency
died as a result of a cytokine storm following intravascular delivery of a huge dose (3.8 ˆ 1013 viral
particles) of Ad5 [4]. This case provided a significant low point in the clinical development of Ad
as a biotherapy, and highlighted the requirement to better understand and refine the dose-limiting
interactions that limit efficacy and promote toxicity clinically. Disseminated infections are generally
associated with high liver and kidney toxicity, and may result in multi-organ failure due to high virus
burden in the blood. Ad infections in immunocompetent and -compromised patients are discussed
in detail in a recent review by Lion and colleagues [3].
Ad was originally isolated from a human adenoid tissue sample in 1953 [5]. The past 60 years
have provided compelling evidence of the tumor-killing (oncolytic) potential of Ad-based vectors.
They infect both dividing and non-dividing cells, and can incorporate large transgenes to their
genome without the risk of integration into the host genome, and are therefore not considered
to be intrinsically oncogenic (unlike some integrating viral vectors). Due to the generally mild
nature of the disease manifestation and long clinical history, Ads are widely considered to be safe
delivery vectors for gene therapy applications. The Ad genome is well-characterized, compact
and largely permissive for a plethora of genetic modifications. Hence novel vector candidates are
continuously being assessed for effective and safe future therapeutics. The latest trends in Ad gene
therapy have included oncolytic Ads (OAds) with a variety of cancer-specificities, tumor vaccines,
cancer immunotherapies and modulation of immune checkpoint control mechanisms (for reviews on
oncolytic Ad-based therapies, see [6–9]).
Ad serotype 5 (Ad5) has been the most commonly used delivery vector for experimental and
clinical purposes, and comprises the majority of gene therapy trials worldwide [10]. However,
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its wider use is severely limited by high levels of pre-existing humoral immunity in the
general population, estimated to be >90% in certain geographical locations such as in sub-Saharan
Africa [11–13]. Neutralizing antibodies (nAbs) directed against the primary antigenic epitopes in the
three major capsid proteins rapidly opsonize and target the systemically-delivered therapeutic vector
for elimination, thus severely hampering its therapeutic efficacy. This review aims to provide an
insight into Ad-mediated immunity and implications for OAd vector design for immune evasion and
selective immune modulation for successful anti-cancer therapies.
1.2. Tissue Tropism
Ads are capable of infecting a wide variety of vertebrate hosts via aerosol droplets in the
respiratory, urinary or gastrointestinal tract (reviewed in [1]), utilizing multiple cellular entry
receptors in a serotype-dependent manner (Table 1). The most widely used cell attachment receptor
for all Ad species, except species B viruses, is the human coxsackie and adenovirus receptor (hCAR).
It belongs to the family of immunoglobulin-like surface molecules and co-localizes in the tight
junctions with zonula occludens-1 (ZO-1) protein on polarized epithelial cells (reviewed in [14])
and is ubiquitously expressed in all human organs and on erythrocytes [15,16]. Following a natural
respiratory tract infection with wild type Ad5, an early event involves the over-expression of the Ad
fiber protein which disrupts tight junctions, thus facilitating viral translocation from the basolateral
to apical surface of the epithelial cells and enabling onward virus spread [17]. Recently, species B
Ads were divided into B1 and B2 subclasses based on their differential receptor usage with species B1
utilizing the membrane cofactor protein CD46 as their primary cellular attachment receptor, whilst
species B2 utilize Desmoglein-2 (DSG-2) [18]. Ad11 has been shown to utilize both CD46 and DSG-2.
Ad3/7/11 binding to DSG-2 has been shown to stimulate epithelial-to-mesenchymal transition (EMT)
that is a central event in carcinogenesis [18], which may limit their use as anti-cancer vectors.
Table 1. Human adenovirus classification, receptor usage and tissue tropism. hCAR, human coxsackie
and adenovirus receptor; DSG-2, desmoglein-2; HSPG, heparan sulfate proteoglycan; VCAM-1,
vascular cell adhesion molecule 1; SR, scavenger receptor; MHC1, major histocompatibility complex
class 1; SA, sialic acid; nd, not determined.
Human Adenovirus Classification and Tropism
Species Serotypes Receptors Tropism
A 12, 18, 31 hCAR Cryptic (enteric,respiratory)
B1 16, 21, 35, 50 CD46 [19], CD80, CD86 Respiratory, ocular
B2 3, 7, 14, 34, 35 DSG-2 [18], CD80, CD86 Renal, ocular, respiratory
B1/2 11 CD46, DSG-2 [18] Ocular, respiratory
C 1, 2, 5, 6 hCAR [20], HSPG, VCAM-1, SR,MHC1-α2
Respiratory, ocular,
lymphoid
D 8-10, 13, 15, 17, 19, 20, 22-30,32, 33, 36-39, 42-49, 51, 53
SA [21], CD46 [22,23], hCAR [22],
GD1a glycan [24] Ocular, Enteric
E 4 hCAR Ocular, respiratory
F 40, 41 hCAR Enteric
G 52 nd Enteric
Whilst Ads primarily utilize the fiber knob:hCAR-mediated pathway for cell entry in vitro,
tropism in vivo, at least following systemic delivery (widely considered as the holy grail for oncolytic
applications), appears to be dictated by a variety of other factors including the high affinity
interaction between human coagulation factors (in particular Factor X, FX) that largely determines
their hepatic tropism following contact with the bloodstream [25,26] (reviewed in [27]). These
“adapter molecules”—multiple vitamin K-dependent coagulation factors—play a central role in Ad5
hepatotropism [28,29] that is mediated by a specific multi-factor interaction between hexon HVRs and
heparan sulphate proteoglycans (HSPGs), expressed on the surface of hepatocytes. This high affinity,
Ca2+-dependent interaction is effectively “bridged” by FX [25,30], a serine endopeptidase circulating
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free in the blood at a concentration of approximately 8 µg/mL. Ad5 HVR5, HVR7 (and possibly
HVR3), located on the top of the hexon trimer [25,31], are known to bind to the γ-carboxylated
glutamic acid (Gla) domain of the FX molecule, guiding the extensive liver sequestration of
Ad5-based vectors [25].
More recently, a potentially critical role for the FX/hexon interaction has been described that
protects the Ad5 capsid from complement-mediated immune attack and destruction by natural
antibodies, therefore casting further doubt over the role of FX as a hepatotropic adaptor or in
protection of the Ad5 virion from immune attacks [32]. Notably, species D Ads have been shown
to exhibit low or abolished affinity to FX and subsequently reduced liver transduction relative to
Ad5 [25], which is likely to have important implications for design of novel vector candidates based
on these serotypes.
1.3. Structural Basis of Immunogenicity
The major antigenic epitopes of the Ad particle are located within the main capsid proteins fiber,
penton and hexon. Herein, the major antigenic determinants of the well-characterized and most
commonly deployed serotype, Ad5, are discussed in further detail.
1.3.1. Hexon
The homotrimeric hexon is the largest (~130 kDa) and most abundant capsid component, with
240 pseudo-hexagonal trimers lining the 20 facets of the virion surface. Hexons can be classified
into H1–H4 based on their interactions with neighboring penton proteins. They have up to nine
HVRs [33] (dependent on the serotype) on the surface-exposed epitopes of the molecule (Figure 2),
which represent major antigenic targets for nAbs following virus challenge [34,35]. Anti-hexon nAbs
can act at both the extracellular level to sterically limit cellular association, or at the intracellular level
to prevent virus uncoating and nuclear entry of viral DNA [36]. It has also been suggested that innate
anti-Ad5 immune responses can be triggered by recognition of FX bound on the hexon protein [37],
while a recent study reports the role of FX in shielding the Ad5 capsid from immune attacks and
subsequent neutralization by natural IgM and complement proteins [32].
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Figure 2. Top view of the Ad5 hexon monomer with the major antigenic epitopes. Hypervariable 
regions (HVRs) 1‒7 [33] shown in different colors; the site for point mutation (E451Q) central for 
ablation of human coagulation factor X (FX) binding [26] is shown in yellow; TET motif central for the 
high affinity interaction with coagulation factor VII (FVII) shown in orange [38]. The model was 
generated in PyMol version 1. 1eval (PDB ID: 3TG7). 
Additionally, Ad5 hexon HVRs have been suggested to be the specific sites determining 
sensitivity to the described innate immune neutralization [39], particularly following intramuscular 
(i.m.) vaccination or vector challenge [40,41]. The hexon harbors the main neutralizing epitope ε that 
can be utilized for serotyping by neutralization tests, while the γ determinant in the fiber knob is 
responsible for hemagglutination properties. However, resulting from extensive intra- and interspecies 
recombination, diagnostic typing is often non-exclusive due to cross-reactivity in hemagglutination 
tests [42]. 
Figure 2. Top view of the Ad5 hexon monomer with the major antigenic epitopes. Hypervariable
regions (HVRs) 1-7 [33] shown in different colors; the site for point mutation (E451Q) central for
ablation of human coagulation factor X (FX) binding [26] is shown in yellow; TET motif central for
the high affinity interaction with coagulation factor VII (FVII) shown in orange [38]. The model was
generated in PyMol version 1. 1eval (PDB ID: 3TG7).
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Additionally, Ad5 hexon HVRs have been suggested to be the specific sites determining
sensitivity to the described innate immune neutralization [39], particularly following intramuscular
(i.m.) vaccination or vector challenge [40,41]. The hexon harbors the main neutralizing epitope
ε that can be utilized for serotyping by neutralization tests, while the γ determinant in the fiber
knob is responsible for hemagglutination properties. However, resulting from extensive intra-
and interspecies recombination, diagnostic typing is often non-exclusive due to cross-reactivity in
hemagglutination tests [42].
1.3.2. Fiber
The Ad5 fiber is a homotrimeric ~62 kDa protein located on the 12 vertices of the icosahedral
capsid. It consists of a globular knob domain containing the receptor-binding domain that mediates
binding to the native receptor hCAR [20] (residues Ser408, Pro409, Tyr477 and Leu485) and distinct
protruding loop structures with the nine main antigenic epitopes (A-I) involved in elicitation of
serotype-specific nAbs [43] (Figure 3). The C terminus of the fiber is a rigid shaft structure, mediating
contact to the underlying penton protein that plays a central role in endosome-mediated entry into
host cells via αvβ3/5 integrins (entry pathway reviewed in [1]).
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Figure 3. Side and top view of the Ad5 fiber monomer. Main antigenic epitopes are highlighted in 
distinct colors (see legend) and hCAR-binding site is indicated in blue [43]. The model was generated 
in PyMol version 1.1eval (PDB ID: 1KNB). hCAR, human coxsackie and adenovirus receptor. 
The fiber plays a key role in mediating viral endosome-cytoplasm transition through the 
detachment of the fiber protein and its membrane lytic activity in the low pH endosome. Both the 
length and flexibility of the fiber protein are central in viral cellular uptake, which has been 
demonstrated by pseudotyping the long Ad5 shaft with short shafts from other serotypes resulting 
in reduced infectivity and attachment [44], as well as by introducing point mutations into the KKTK 
motif within the fiber shaft showing impaired flexibility and drastically reduced cell transduction 
[44,45]. The KKTK motif was previously considered to be involved in Ad5-mediated hepatic delivery 
via HSPG interactions [46,47]. More recent studies, however, demonstrate this motif to be non-
essential for this interaction [48], and rather that the KKTK motif exists at an essential “hinge region” 
within the shaft protein, where modification of this motif renders the fiber inflexible and unable to 
interact with cellular αvβ3/5 integrins [49,50]. 
The exact target of anti-fiber nAbs remains a hot topic of debate, with compelling evidence that 
the antigenic loops within the fiber knob form the major immunodominant domains [40,51], at least 
following a native Ad5 infection [52]. Ad entry into the airway epithelia results in over-expression of 
the fiber protein [17] and thus directly exposes the fiber to the innate immune recognition mechanisms 
as it is the most abundant viral component in the early stage of infection. There is significant 
controversy surrounding the determination of primary antigenic determinants of the Ad5 virion, as 
earlier reports suggest that the fiber protein does not play a central role in nAb production [53], while 
more recent studies have demonstrated its involvement in eliciting the majority of anti-Ad5 nAbs 
following a natural inoculation [52]. The role of anti-hexon and -fiber nAbs is discussed further in 
Section 1.6. 
Figure 3. Side and top view of the Ad5 fiber monomer. Main antigenic epitopes are highlighted in
distinct colors (see legend) and hCAR-binding site is indicated in blue [43]. The model was generated
in PyMol version 1.1eval (PDB ID: 1KNB). hCAR, human coxsackie and adenovirus receptor.
The fiber plays a key role in mediating viral endosome-cytoplasm transition through the
detachment of the fiber protein and its membrane lytic activity in the low pH endosome. Both
the length and flexibility of the fiber protein are central in viral cellular uptake, which has
been demonstrated by pseudotyping the long Ad5 shaft with short shafts from other serotypes
resulting in reduced infectivity and attachment [44], as well as by introducing point mutations into
the KKTK motif within the fiber shaft showing impaired flexibility and drastically reduced cell
transduction [44,45]. The KKTK motif was previously considered to be involved in Ad5-mediated
hepatic delivery via HSPG interactions [46,47]. More recent studies, however, demonstrate this motif
to be non-essential for this interaction [48], and rather that the KKTK motif exists at an essential
“hinge region” within the shaft protein, where modification of this motif renders the fiber inflexible
and unable to interact with cellular αvβ3/5 integrins [49,50].
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The exact target of anti-fiber nAbs remains a hot topic of debate, with compelling evidence that
the antigenic loops within the fiber knob form the major immunodominant domains [40,51], at least
following a native Ad5 infection [52]. Ad entry into the airway epithelia results in over-expression of
the fiber protein [17] and thus directly exposes the fiber to the innate immune recognition mechanisms
as it is the most abundant viral component in the early stage of infection. There is significant
controversy surrounding the determination of primary antigenic determinants of the Ad5 virion,
as earlier reports suggest that the fiber protein does not play a central role in nAb production [53],
while more recent studies have demonstrated its involvement in eliciting the majority of anti-Ad5
nAbs following a natural inoculation [52]. The role of anti-hexon and -fiber nAbs is discussed further
in Section 1.6.
1.3.3. Penton base
The third major building block of the viral capsid is the penton base, a homopentameric ~82
kDa protein (Figure 4) located on the base of each fiber trimer. While the fiber is responsible for Ad5
particle attachment on the host cell surface, the penton is involved in viral internalization, mediated
by binding to the vitronectin-binding αvβ3/5 integrins on the cell surface [54] via the conserved
integrin-binding Arg-Gly-Asp (RGD) epitope (amino acid residues 485-488 [55,56]). The penton has
three immunodominant neutralizing epitopes—one of which overlaps with the RGD motif—that
contribute to virus neutralization mainly at the internalization step of the infectious cycle [57].
Anti-RGD antibodies have been suggested to have a non-neutralizing role in Ad infection [57].
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Figure 4. The Ad2 penton base monomer. The three main antigenic sites [57] are highlighted in blue, 
integrin-binding motif Arg-Gly-Asp (RGD) labelled in red [56,58]. The structure was constructed in 
PyMol version 1.1eval (PDB ID: 1X9P). 
Ad5 binding to cellular αvβ3 integrins on marginal zone macrophages (MZMΦs) via the penton 
RGD motif has been shown to contribute to innate immune activation by triggering the IL-1α 
activation and subsequent IL-1RI-dependent induction of cytokine and chemokine C-X-C motif 1 
(CXCL1) and CXCL2 production, as was demonstrated in a study utilizing an Ad5 vector with RGD 
motif deletion (Ad5RGDΔ) [59]. Ad5ΔRGD vectors with Ad35-pseudotyped fiber (short shaft [60]) 
have been shown to have retained cellular attachment but an impaired internalization, which may 
indicate a role for this motif in endosomal escape and the importance of penton–integrin interactions 
for CD46-utilising species B Ads [61]. Additionally, Ad5 vectors carrying a point mutation that 
abolishes integrin-binding (RGD/RGE) has been shown to result in reduced splenic uptake and 
attenuated inflammatory responses in mice [62]. These observations suggest a central role for RGD 
motif not only in the viral internalization, but also in the activation of anti-Ad innate immune responses. 
1.4. Innate Immune Responses 
The three major capsid proteins, early proteins E1A, E1B, E2 and E4, and virus-associated non-
coding RNAs VA-I and VA-II, have all been implicated to be central in the synergistic activation of 
innate immune responses that lead to inflammation and vector clearance (reviewed in [63,64]). 
Following systemic Ad5 vector administration, the virus is rapidly recognized and coated by proteins 
of the complement cascade [65,66], Kupffer cells (KCs), platelets, erythrocytes [15) and IgM antibodies 
that readily recognize repetitive pathogen structures such as virus capsids [67] (in vivo blood 
interactions reviewed in [27]). Human (but not murine) erythrocytes express hCAR and complement 
receptor 1 (CR1) and are thus capable of rapid coating and inactivation of the Ad5 particles following 
Figure 4. The Ad2 penton base monomer. The three main antigenic sites [57] are highlighted in blue,
integrin-binding motif Arg-Gly-Asp (RGD) labelled in red [56,58]. The structure was constructed in
PyMol version 1.1eval (PDB ID: 1X9P).
Ad5 binding to cellular αvβ3 integrins on marginal zone macrophages (MZMΦs) via the
penton RGD motif has been shown to contribute to innate immune activation by triggering the
IL-1α activation and subsequent IL-1RI-dependent induction of cytokine and chemokine C-X-C
motif 1 (CXCL1) and CXCL2 production, as was demonstrated in a study utilizing an Ad5 vector
with RGD motif deletion (Ad5RGD∆) [59]. Ad5∆RGD vectors with Ad35-pseudotyped fiber (short
shaft [60]) have been shown to have retained cellular attachment but an impaired internalization,
which may indicate a role for this motif in endosomal escape and the importance of penton–integrin
interactions for CD46-utilising species B Ads [61]. Additionally, Ad5 vectors carrying a point
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mutation that abolishes integrin-binding (RGD/RGE) has been shown to result in reduced splenic
uptake and attenuated inflammatory responses in mice [62]. These observations suggest a central
role for RGD motif not only in the viral internalization, but also in the activation of anti-Ad innate
immune responses.
1.4. Innate Immune Responses
The three major capsid proteins, early proteins E1A, E1B, E2 and E4, and virus-associated
non-coding RNAs VA-I and VA-II, have all been implicated to be central in the synergistic activation
of innate immune responses that lead to inflammation and vector clearance (reviewed in [63,64]).
Following systemic Ad5 vector administration, the virus is rapidly recognized and coated by proteins
of the complement cascade [65,66], Kupffer cells (KCs), platelets, erythrocytes [15] and IgM antibodies
that readily recognize repetitive pathogen structures such as virus capsids [67] (in vivo blood
interactions reviewed in [27]). Human (but not murine) erythrocytes express hCAR and complement
receptor 1 (CR1) and are thus capable of rapid coating and inactivation of the Ad5 particles following
systemic delivery [15]. Ad5-based vectors are efficiently opsonized by complement factors—even
in the absence of nAbs—which indicates central involvement of this pathway in both innate and
adaptive arms of anti-Ad immunity [65]. Rapid chemokine and cytokine production, as well as
Ad5-induced thrombocytopenia mediated by p-selectin and von Willebrand factor (vWF) [68], are
all elicited in a C3-dependent manner, with the help of other complement factors [66] such as C2 and
C1q, (reviewed in [27]). Furthermore, Ad5 is extensively sequestered by the liver [69], leading to
acute transaminitis, vascular damage and even severe toxicities [70].
The spleen is another major off-target site for Ad vectors. Systemic Ad delivery results in
vector binding to β3 integrins via the penton RGD motif on MZMΦs and leads to accumulation
in the spleen, which initiates IL-1α-mediated activation of chemokine- and complement cascade,
promoting polymorphonuclear leukocyte (PMN) activation and local inflammation [59]. Recent
publications have also reported novel roles for the non-inflammatory factor of the coagulation
pathway, namely FX, indicating its involvement in Ad5 virus shielding from neutralization by natural
IgM antibodies and subsequent activation of the complement cascade [32]. Conversely, decoration of
the virus particle with host FX has also been suggested to function as a pathogen-associated molecular
pattern (PAMP), triggering innate immune responses via the Toll-like receptor / nuclear factor κB
(TLR/NF-κB) pathway [37].
1.5. Adaptive Immune Responses
Therapeutic Ad vector delivery results in long-lasting humoral and cellular immune responses
in the human host [71]. Antigen-presenting cells (APCs)—dendritic cells (DCs) and immature
macrophages—recognize PAMPs and direct DC maturation and T cell activation, leading to
subsequent adaptive immune responses against the pathogen (reviewed in [72]). Ad infection elicits
activation of NK cells [73] cytotoxic CD8+ T cell [74] and memory CD4+ T cell responses [75].
In addition to containing major nAb epitopes as described earlier [34,35,74], the highly conserved
regions of the hexon protein have been identified to contain at least three major CD4+ T cell
epitopes [75,76]. Systemic production of serotype-specific IgM, IgA and IgG [77] and nAb
seroconversion has been reported to occur within 2-4 weeks of the primary virus exposure [78].
There is evidence that the intensity of humoral immune responses may be determined by vector
administration site and pre-existing nAb titers rather than the therapeutic dose [79]. Different human
and animal serotypes have been shown to have minimal levels of cross-reactivity, as nAbs seem to be
specific to the homologous virus [80].
Anti-Ad nAbs comprise primarily fiber-, penton- and hexon-specific IgG1, IgG4 and IgA
antibodies (reviewed in [72]) that can inactivate the virion at different points of its infectious
cycle [34,53]. Anti-fiber nAbs seem to contribute to the blocking of initial virus attachment on the
cell surface by extracellular virion aggregation [81], while anti-penton nAbs may be responsible
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for inhibiting the internalization step [57] and a proportion of anti-hexon nAbs potentially account
for intracellular, post-entry neutralization [36], although this remains controversial. It has been
demonstrated that 1.4 individual serotype-specific anti-hexon nAbs are needed for full neutralization
of Ad2 [82]. Intriguingly, this study also describes how the neutralization efficiency of anti-penton
nAbs can be increased from 50% to 100% efficiency by lowering the pH from 7 to 5, which is
presumably due to the exposure of the penton antigenic epitopes and subsequent interaction with
anti-penton nAbs.
1.6. Natural vs. Induced Immunity
Anti-fiber nAbs have been shown to emerge first after the delivery of therapeutic Ad vector,
followed by generation of anti-penton nAbs and anti-hexon nAbs, suggesting that all three are needed
for a full synergistic neutralizing effect [83]. However, there has been considerable controversy
surrounding the specificity and immunogenicity of the capsid protein-induced nAbs. In addition
to nAbs having specificities against different capsid proteins, they also seem to vary based on the
route of inoculation. Reports have suggested a primary role for anti-hexon nAbs in vaccine-induced
immunity [34] and anti-fiber nAbs following natural infection [52,84]. According to Cheng and
colleagues, nAbs elicited by replication-deficient Ad5 vaccine vectors in seronegative individuals
were directed against capsid components other than the fiber, while nAbs elicited by natural infection
with wild type viruses mainly were directed against the fiber. Previously seropositive individuals had
nAbs against both fiber [84] and other capsid components after vaccine challenge. On the contrary,
a recent study reports only subtle differences between the specificity of nAbs relative to the infection
type (vaccination vs. natural), suggesting the immunodominance of hexon and a subdominant
assisting role for anti-fiber nAbs in neutralizing immunity [40].
The understanding of pre-existing Ad-mediated immunity is crucial for therapeutic vector
design, which has been demonstrated by unsuccessful clinical trials in the past. An Ad5-based
non-replicating vector MRK-Ad5, expressing HIV-1 clade B proteins Gag, Pol and Nef, was used as
an HIV-1 vaccine candidate in the phase II, double-blind, randomized, placebo-controlled STEP trial
involving ~3000 volunteers at 34 sites in North America, the Caribbean, South America and Australia,
that was initiated in 2005 but was halted shortly afterwards [85]. Unexpectedly, the incidence of
HIV-1 infection was reported 2.3-fold higher in the individuals with pre-existing anti-Ad5 immunity,
relative to the respective placebo group, while the risk was not increased in seronegative individuals
(reviewed in [86]). These observations were completely unexpected as the connection between the
serological status and susceptibility to HIV-1 infection remains unclear. This strongly demonstrates
the necessity for fully understanding the underlying factors that affect the immunogenicity of Ad
vectors carrying heterologous components intended for gene therapy or vaccine applications.
1.7. Prevalence of Pre-Existing Humoral Immunity
Ad5 is a common respiratory virus infecting human populations worldwide. Due to its high
seroprevalence, the majority of human populations carry anti-Ad5 nAbs that are highly capable of
neutralizing the virus upon a secondary infection or re-exposure to a therapeutic vector. The highest
seroprevalence rates of anti-Ad5 immunity are reported in the developing world, sub-Saharan Africa
in particular [87], while pre-existing nAbs levels against rare human serotypes from subgroups B and
D appear to be substantially lower in the studied populations [11,12,87].
The prevalence of nAbs directed against subgroup C viruses Ad5 and Ad6, and subgroup D
viruses Ad26 and Ad36 was evaluated in an international study [12] that revealed overall high
prevalence of pre-existing anti-Ad5 immunity (85.2%), Thailand having close to 100% prevalence
(Figure 5). Both subgroup D viruses had remarkably lower seroprevalence, overall values
being 58% for Ad26 and 46.4% for Ad36. Several studies have evaluated the age-dependence
of anti-Ad immunity in different populations. In pediatric populations in sub-Saharan Africa,
maternally-derived anti-Ad5 Ab titers were high until six months of age, then remained low until
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the age of two years then increasing rapidly until seroprevalence rates reached adult levels by seven
years of age [88]. It is thus crucial to take into account the variable seroprevalence rates between
different Ad serogroups when selecting new Ad vector candidates for patients from different age
groups, particularly when intended for systemic delivery.Journal 2015, 7, page–page 
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1.8. Vector Neutralization by Ovarian Ascites
Due to the significant challenges associated with achieving targeted tumor specific delivery
of Ad via the systemic route, localized intratumoral (i.t.) delivery would circumvent many of
the dose-limiting vector–host interactions. Ovarian cancer is the leading cause of death from
gynecological cancers and the fifth most common cancer in women in the UK [89]. The advanced
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stage of the disease is characterized by high frequency of metastases and build-up of malignant
ovarian ascites that represents the chemo-resistant and recurrent disease with poor prognosis
(reviewed in [90]). Large volumes of fluid cause major discomfort and pain in the patients, requiring
routine drainage (paracentesis) to temporarily ease the patients’ symptoms [91]. Ovarian cancer
presents an appealing target for OAd virotherapy due to the potential of direct vector administration
intraperitoneally (i.p.), thus having access to both primary and metastatic tumors, as well as other
tumor-associated cell types residing in the ascitic fluid.
Ascites has a protein content similar to serum, including substantial levels of anti-Ad5 nAbs [92]
and is highly capable of neutralizing Ad5-based vectors [93,94]. In a study by Hemminki and
colleagues, levels of nAbs were compared in both serum and ascites following i.p. delivery of Ad5
vector into ovarian cancer patients. Induction of nAb production was rapid in both serum and ascites
following viral delivery, and nAb titers were not affected by the administered dose. Surprisingly,
Ad transgene expression was relatively unaffected by ascites, albeit likely due to 4-fold lower nAb
titers in ascites as compared to serum nAb titers [92]. Removal of the fluid prior to OAd virotherapy
may help reduce vector neutralization and improve bioavailability for active tumor targeting, thus
improving efficacy. Ascitic fluid contains diverse cell populations, one of which is epithelial ovarian
cancer cells (EOC) that can be readily cultured from the patient-derived ascites [95,96]. These ex vivo
cultures represent an important platform for functional analyses of ovarian cancer cell properties [97]
and assessment of the interplay between the fluid and its components may provide essential insight
into the possibilities for treating disseminated peritoneal cancers with Ad-based i.p. therapies in
the future.
1.9. Oncolytic Adenoviruses—the Clinical History
Ads are inherently lytic against their host cells, releasing the virus progeny to the neighboring
cells. OAds can be generated by a number of genetic engineering strategies by combining
attenuation of genes essential for viral replication to achieve high selectivity and safety, and
incorporation of genes that are expressed only in neoplastic cells for the generation of cancer-specific
vectors. Insertion of cancer-selective promoters is a strategy that can be utilized to generate
conditionally-replicative Ad vectors (CRAds), promoting restricted lysis of cancer cells with defective
signaling pathways and/or characteristic tumor microenvironment. Ad vectors have undergone
three generations of development, involving the deletion of early genes E1, E2, E3 and E4 that are
central for viral replication, viral DNA transcription/replication of late genes, modulation of immune
responses and metabolism of virus mRNA/host protein synthesis, respectively. The first generation
Ads were modified to carry an E1/E3 mutation, a basic attenuating mutation for generation of
replication-deficient vectors, while second generation Ads had an E4 deletion in addition to E1
and/or E3 deletions (reviewed in [6,98]).
The past decade has marked the approval of the first oncolytic Ad5-based vector ONYX-015
for treatment of head and neck cancers in China [99]. In healthy tissues, tumor antigen p53 is the
guardian of DNA damage and stress, and activates DNA repair mechanisms, initiates apoptosis,
prevents angiogenesis and controls excessive cell proliferation by cell division arrest at the G1/S stage
of the cell cycle, among its other diverse functions (reviewed in [100]). Mutations in the p53 gene can
lead to uncontrolled cell division and carcinogenesis, which is why its proper functionality is crucial
for the maintenance of healthy tissues. ONYX-015 vector carries a complete deletion of the E1B 55 kD
gene (∆1520) that renders it capable of selectively infecting neoplastic cells with a defective p53 tumor
suppressor pathway [101]. However, only an estimated 50% of all cancer patients carry mutations
in the p53 gene [100]. Therefore, complementing strategies are urgently needed for cancer patients
who have a functional p53 pathway and are thus refractory to these treatments. On the contrary,
~97% of ovarian cancer patients with high-grade serous (HGS) carcinoma have been tested positive
for defective p53 pathways in large scale genomic analyses [102,103], highlighting the potential of
OAd-based therapies targeting this pathway in ovarian cancer.
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It has been suggested that the retinoblastoma protein (pRB) tumor-suppressor pathway may be
defective in all human cancer types [104], which indicates the feasibility of targeting this pathway
for cancer therapies [105]. A 24-base pair deletion (∆24; dl922-947) in the pRB-binding domain of
E1A has been shown to efficiently restrict viral replication in proliferating cells with a defective pRB
pathway [105], enabling transition from G1 to S phase [104]. An Ad5-based oncolytic ICOVIR-5
targeted to tumors with a defective pRB pathway, combines E1A transcriptional control by EF2
promoter mutation, ∆24 mutation and an RGD-4C modification in the fiber HI loop [106,107], is
currently undergoing phase I clinical studies for treatment of advanced melanoma and has shown
promising safety and anti-tumor efficacy [107]. An oncolytic HYPR-Ad5 vector developed by Post
and colleagues utilizes hypoxia-dependent E1A expression and subsequent selective lysis of hypoxic
cells that are the dominant population of cells resistant to chemo- and radiotherapies in solid
tumors [108].
Recently, a novel Ad5 vector ORCA-010 carrying a novel mutation (T1) has shown enhanced
oncolytic efficacy and safety in pre-clinical in vivo studies, and is estimated to be significantly
more potent than the licensed ONYX-015 vector [109]. The T1 mutation contains insertion of a
single adenine base at position 445 within the endoplasmic reticulum (ER) retention domain of
the E3/19K gene that has been shown to greatly enhance oncolytic potency of Ad5, presumably
due to increased release of virus progeny from the ER and efficient spread within the tumor
mass [110]. ONCOS-102—a chimaeric Ad5/knob3 vector armed with the potent immunostimulatory
granulocyte-macrophage colony stimulating factor (GM-CSF)—has completed phase I clinical studies
with increased cancer-specific CD8+ T cell responses and good safety profile in heavily pre-treated
patients with injectable solid advanced tumors [111] and is ready to enter phase II/III studies. Phase
I studies demonstrated enhanced immunologic response, good safety and a significant correlation
between anti-viral and anti-tumor T cells, while neither safety nor efficacy were affected by the Ad5/3
fiber pseudotyping [112].
Rapid elimination of the therapeutic vector from the bloodstream following systemic delivery
occurs frequently via recognition by pre-existing anti-Ad5 nAbs, which severely limits the use of this
serotype for oncolytic applications and thus the use of alternative serotypes is required. Recently, a
novel “directed evolution” approach was used to create the first wholly non-Ad5-based oncolytic
species B Ad. ColoAd1 (also known as enadenotucirev, EnAd), a complex and highly potent
chimaeric Ad3/Ad11p virus (∆E1A/E1B), was generated through forced evolution via recombination
of a pool of Ads from different subgroups on tumor cell lines. ColoAd1 has a small 24 bp
deletion in the region encoding E4orf4 that, in the context of Ad5, induces protein phosphatase 2A
(PP2A)-mediated, p53-independent apoptosis [113]. However, the oncolytic mechanism of ColoAd1
seems to be entirely apoptosis-independent and its enhanced potency may be related to the chimeric
E4 region that may alter the expression of additional, yet unknown genes [114]. ColoAd1 has shown
significantly improved selectivity and cancer-killing as compared to the ONYX-015 [114], and phase
II/III clinical trials are currently ongoing for the treatment of colon cancer and other solid tumors.
Furthermore, superior blood persistence and oncolytic activity was observed for ColoAd1 in the
highly neutralizing environment of the whole human blood, which indicates its potential suitability
for i.v. treatment of disseminated tumors [115].
Ad vectors are highly potent immunotherapeutic agents and can successfully be utilized for
prime-boost regimens. However, their efficacy as monotherapies remains frustratingly low and
therefore the combination of potent Ad vectors with existing gene-, chemo- and radiotherapies is
likely to result in better therapeutic responses due to multiple mechanisms of cell killing, eradication
of the malignant tumor tissues and long-lasting systemic responses (reviewed in [116,117]). Despite
of the recent advances in the Ad virotherapy field, major challenges still remain. It is clear that
innovative strategies for vector design, coupled with selective immune stimulation within the tumor
microenvironment, hold significant promise for effective cancer eradication.
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2. Therapeutic Vector Design for Host Immune Evasion
2.1. Introduction
Ad vectors elicit extensive anti-viral humoral and cellular immune responses in their host, which
severely impair the clinical outcome of oncolytic virotherapies due to premature clearance of the
therapeutic vector. Successful Ad vector development should therefore involve careful consideration
of viral particle masking strategies in order to achieve reduced immune recognition and improved
bioavailability for the target tissue. The Ad vector can be modified genetically or chemically, to carry
adapter molecules, or pseudotyped to contain small domains or whole capsid proteins from less
seroprevalent human and animal serotypes, in order to combat the hostile neutralizing environment
encountered in the human body. One of the novel approaches in the oncolytic virotherapy field is
“biological” shielding of reovirus vectors with potent immune cells [118]. Intriguingly, the decorated
reovirus particles were not only protected from pre-existing nAbs present in ovarian ascites, but were
also capable of combining efficient oncolysis with immune priming by inducing innate and specific
anti-tumor adaptive immune responses. This study describes a novel dual cancer therapy that could
potentially be adapted to Ad-based applications.
2.2. Ads with Low Seroprevalence
Anti-Ad5 humoral immunity may be circumvented by using less common serotypes that have
low natural seroprevalence in the general human population. Additionally, utilization of other than
species C Ads is appealing due to their variable receptor and tissue tropisms, as the expression
of the primary species C receptor hCAR has been shown to be down-regulated in progressive
cancers [119,120], and may therefore not be the optimal tumor target. Ad vectors have been
extensively modified by exchanging specific capsid components with those from less seroprevalent
or immunogenic serotypes (virus chimeras reviewed in [121]). Chimeric or pseudotyped vectors
with altered cell selectivity, antigenicity and tissue tropism have been successfully tested in both
pre-clinical [11,35,52,53,122,123] and clinical trials [107,111,114] over the past decades.
Ad subgroup D has the largest diversity of viruses, coupled with other advantages such as
low seroprevalence rates [11] and decreased intrinsic hepatotropism due to low affinity to FX [25].
They appear capable of infecting their host cells via multiple surface receptors, such as CD46 [22,23],
hCAR [22], sialic acids [21] and GD1a glycan [24], whilst the involvement of additional receptors
has not yet been ruled out. A recent study compared 16 different species D Ads for their ability to
spread in tumor mass [124]. Ad9 was found to be the most efficient at infecting both hCAR-negative
and -positive cells, and thus presents an appealing alternative serotype for cancer applications.
Barouch and colleagues demonstrated Ad35, -26 and -48 vaccine vectors to be more immunogenic
in rhesus monkeys than the hCAR-utilizing Ad5, resulting in high levels of innate anti-viral and
pro-inflammatory cytokine responses [125]. In a recent study by Camacho and colleagues, species
D viruses Ad26, -28 and -48 were shown to be more efficient at cell transduction via intranasal
delivery, while Ad5 was the most efficient in i.m. delivery [126]. Importantly, i.m. transduction levels
were restored in mice ubiquitously expressing human CD46. Additionally, Ad26 had significantly
improved DC transduction as compared to Ad5 that has been shown to only infect these cells via a
lactoferrin and DC-SIGN-mediated pathway [127].
An interesting study compared the replication efficacy and oncolytic potency of 15 different
species B, C, D and F viruses in B cell cancer cell lines and primary B cell cancers [128]. Species
D viruses were shown to have the overall most efficient oncolysis in a panel of B cell cancer cell lines,
primary patient marginal zone lymphoma cells, and primary patient CD138+ myeloma cells in vitro.
Ad26, -45 and -48 showed markedly improved oncolysis compared to all other viruses (including
Ad5), while a single i.t. administration of Ad26 and Ad45 resulted in a significantly reduced growth
of in vivo lymphoma xenografts.
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Mastrangeli and colleagues compared intratracheal administration of Ad4 (species E) and Ad30
(species D) with Ad5 administration, demonstrating no cross-reactivity between the viruses from
different subgroups [129]. In this study, Ad4 and Ad30 were capable of efficiently transducing the
airway, regardless of a prior exposure to Ad5. According to the authors, these findings may have
potential translational applications in the treatment of respiratory manifestations of cystic fibrosis
to overcome the pre-existing immunity in the airways, when repeated administration is required.
The same group approached the problem by using an Ad2 vector from subgroup C, showing
that pre-existing immunity was indeed efficiently circumvented but the persistence of transgene
expression was compromised [130].
2.2.1. Pseudotyped/Chimeric Vectors
Ad vectors have been modified by switching the major capsid components into domains
from less seroprevalent or immunogenic serotypes (for a review, see [121]). Substituting Ad5
hexon and fiber domains containing the major immunogenic epitopes with those from rare
serotypes, is becoming a common vector design strategy and multiple candidates are assessed
in a number of pre-clinical studies [35,52,53,122]. Exchange of Ad5 hexon HVRs with low
seroprevalence Ad48 HVRs (Ad5HVR48] has been shown to result in altered vector immunogenicity
in recent studies. An Ad5HVR48 vector expressing simian immunodeficiency virus Gag protein
efficiently escaped anti-Ad5 nAb responses and showed comparative immunogenicity to the parental
Ad5 [35]. However, subsequent in vivo studies by Coughlan and colleagues with Ad5HVR48 showed
significantly increased toxicity and immunogenicity in mice following i.v. delivery, despite favorably
decreased hepatotropism [131]. More recently, Teigler and colleagues demonstrated that Ad5HVR48
was indeed capable of evasion from pre-existing anti-Ad5 nAbs but displayed reduced hepatotoxicity
and had similar T cell responses to Ad5, suggesting improved safety and reduced immunogenicity for
this vector, relative to Ad5 [132]. These conflicting observations highlight the unpredictable nature of
chimeric Ad vectors and reinforce the importance of rigorous preclinical evaluation to fully delineate
the immunogenic properties of the recombinant vectors.
Another widely exploited genetic modification approach is the swapping of either the Ad5
fiber knob domain or complete fiber protein with rare Ad serotypes. Fiber pseudotyping has been
shown to result in altered innate [133] and adaptive immune activation [30,134], which implicates
an important role for this genetic modification strategy in Ad vector design. However, a study
performed 20 years ago reports that Ad5 fiber replacement with Ad7 (species B) fiber did not change
the immunogenicity of the vector, despite successfully altered tropism [53]. Similarly, Ophorst and
colleagues have reported increased DC transduction and T cell activation in vivo using an Ad35
fiber-substituted Ad5 vector, but no protection from anti-Ad5 immunity [122]. In contrast, Särkioja
and colleagues achieved substantial protection from nAbs in mice treated with fiber-modified Ad5
vectors [52]. In this study, Ad5 fiber knob domain pseudotyped with Ad3 fiber knob (Ad5/3) showed
increased gene delivery in presence of low and high nAb titers, in comparison to Ad5. Additionally,
while anti-Ad5/3 nAbs were able to neutralize Ad5 only marginally, anti-Ad5 nAbs neutralized Ad5
and blocked gene delivery entirely. However, higher nAb titers induced by triple immunization
with Ad5/3 were capable of cross-neutralization of Ad5, which indicates the involvement of other
neutralizing epitopes either within fiber shaft or other capsomers.
Denby and colleagues pseudotyped Ad5 vectors with fibers from a species B virus Ad16 and
two species D viruses Ad19p and Ad37 and showed equal or improved transduction of vascular
endothelial and smooth muscle cells (SMCs), as compared to Ad5 [135]. Parker and colleagues
evaluated a panel of pseudotyped Ad5 vectors with fiber derived from subgroup D Ads Ad17,
-24, -30, -33, -45 and -47 and showed that these vectors directly interacted with FX and efficiently
transduce the liver, thus demonstrating that the interaction with FX is not fiber-mediated [48].
However, neither of the above-mentioned studies compared the antigenicity of the fiber-pseudotyped
vectors, which would be an intriguing next step in assessment of these candidates for therapeutic
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applications. An interesting study by the same group reports that pre-existing immunity can be
partially bypassed by pseudotyping Ad5 with fiber from species D virus Ad45 (Ad5/F45) [30] that
had previously shown high levels of FX-mediated cell binding and transduction [48]. This study
demonstrated greatly improved protection for Ad5/F45 from nAbs in the presence of 2.5% sera that
largely neutralized the control Ad5 vector, indicating that nAbs are at least partially directed against
the fiber protein and may thus contribute to extracellular neutralization [82].
As for pseudotyping with subgroup B viruses, an Ad5-based Ad35 fiber-chimeric virus
(Ad5T*F35++) was shown to exhibit improved vascular cell transduction and protection from
anti-Ad5 nAbs in human sera [136]. In this study, 33% of 102 human serum samples neutralized
Ad5 by a minimum of 90%, while only 18% of the sera were capable of neutralizing Ad5T*F35++
at similar levels. In addition to having the fiber protein from Ad35, Ad5T*F35++ carries a mutation
(T*) that ablates FX interactions [137], for combining potential immune evasion with efficient liver
de-targeting, which is an important consideration in Ad vector design. Furthermore, when the Ad35
fiber pseudotyping was coupled with penton pseudotyping (Ad5/F35/P35), this vector was capable
of transducing human SMC cultures in vitro, intact mouse aortas from CD46-transgenic mice ex vivo
as well as human saphenous vein ex vivo at significantly higher levels than either of the control vectors
Ad5 or Ad/F35 [138]. The promising results suggest potential utility of this strategy for vascular gene
therapy and other tissues with high levels of CD46 but low levels of hCAR expression.
Accelerated, random evolution may be utilized for generation of a pool of potent recombinant
viruses with altered virulence, tropism and immunogenic properties. This novel strategy mimicking
the inherent random recombination occurring between different Ad serotypes, has recently been
introduced into the field of Ad vector design (discussed in Section 1.9). Multiple Ad serotypes
from various subgroups were passaged on a panel of cancer cell lines, subjecting them to random
recombination and thus directing the emergence of a chimaeric Ad3/11p serotype (ColoAd1) [114].
ColoAd1 has shown superior oncolytic properties on colon cancer cell lines as compared to the
previously developed OAds [114], and has paved its way for phase I/II clinical trials. The vector
carries a large deletion in the E3 region, a small 24 bp deletion in the E4 region and a chimaeric
Ad3/Ad11p E2B region such that the pTP and DNA pol regions have been swapped to those from
a species B1 virus Ad3. Its major capsid proteins appear to originate from a species B2 virus Ad11p,
which suggests uptake via the CD46/DSG-2 pathway. ColoAd1 has been found to have a superior
blood persistence, as its oncolytic efficacy was only marginally deteriorated in pooled human sera and
whole blood [115]. Evidently, that is a highly advantageous feature for an oncolytic vector intended
for i.v. treatment of disseminated solid tumors.
Taken together, the synergistic role of anti-hexon and anti-fiber humoral immunity indicates
that HVR substitutions are not likely to fully overcome the constrains of pre-existing immunity [84].
The penton protein plays a pivotal role in the early steps of Ad infection through αvβ3/5 integrin
binding, and is involved in the early stages of anti-viral immune recognition [54,59], as discussed
in Section 1.3.3 of this review. Modifying the penton RGD motif may therefore have important
implications in the modulation of Ad vector design. αv integrin-binding mutation RGD/RGE has
been shown to lead to 5-fold reduced uptake in splenic uptake and drastically reduced antiviral
inflammatory responses [62]. Conclusively, it may be beneficial to combine penton ∆RGD or
RGD/RGE modifications with hexon and fiber substitutions and tropism-modifying mutations for
development of vectors capable of efficient immune escape.
2.2.2. Non-Human Vectors
Non-human or “xeno” Ads have been evaluated for potential use as therapeutic vectors and
are gaining increasing interest due to three advantages over human Ads: (1) lack of pre-existing
neutralizing immunity; (2) relatively efficient transduction of human cells and (3) altered tissue
tropisms. The variability in receptor usage is a major advantage that could allow targeting of
various clinically-relevant cell types and thus bypassing the limitations of hCAR-mediated cell entry.
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Additionally, animal Ads have very low pathogenicity in their host, are replication-defective in
human cells and can tolerate longer exogenous DNA inserts (transgenes) than human Ads. The
use of non-human Ad serotypes such as canine Ad2 (CAV-2), bovine Ad3, porcine Ad3, ovine
Ad7, murine Ad1, several simian, and fowl Ads as potential gene delivery vehicles is discussed
in great detail in a recent comprehensive review [139]. Notably, Kremer’s group have successfully
studied CAV-2 for the treatment of neurological diseases due to its low immunogenicity, selective
CAR-mediated neuronal transduction, efficient axonal spread and long-lasting bioavailability for the
mammalian brain (reviewed in [140]). Due to these advantageous features, this vector may hold
potential for the treatment of tumors located within the central nervous system (CNS) and thus
warrants further investigation.
Several studies have reported strategies for non-human Ad or pseudotyped chimeric vector
engineering. Bradley and colleagues showed that an Ad5-based vector with HVRs substituted
from Ad48 serotype and fiber substituted from a chimpanzee virus AdC68 (utilizes CAR) largely
evaded pre-existing anti-Ad5 nAbs in neutralization assays with mouse and human sera while
retaining its functionality [40]. Ovine [141] and porcine Ads [142] have been shown to infect human
and murine cells at comparable levels to human Ads, and to be protected from neutralization
by pre-existing anti-human Ad nAbs. The lack of cross-reactivity has potential implications for
vector re-administration for prime-boost vaccine regimens, as alternating the delivery of human
Ad- and supplementing animal Ad-based vectors could be used to overcome vector neutralization
that frequently renders viral gene therapy inefficient [143]. In addition to neutralization evasion,
their CAR-independent tropisms may open new avenues for the treatment of various target tissues.
A study describes a chimeric Ad5 pseudotyped with canine Ad2 fiber that was shown to transduce
CAR-deficient cells at 30-fold increased efficiency relative to Ad5, but fails to report any potential
alterations on vector immunogenicity [144].
2.3. Genetic Masking
Tropism-modification within the main capsid proteins, achieved by genetic engineering
to incorporate short heterologous targeting peptide sequences, has been widely investigated
(reviewed in [27,145]). These strategies could potentially be utilized for masking of the Ad antigenic
epitopes alike, as the insertion of peptides could favorably shift antigenic recognition away from
the major antigenic epitopes. The fiber protein has been the most frequently modified for these
purposes [52,146], due to the location of major antigenic epitopes within the knob domain [43],
its native role in primary cell tethering, and its tolerance of genetic manipulation.
2.3.1. Heterologous Peptide Incorporation within the Fiber
Previous exposure to Ad elicits the production of anti-Ad nAbs that rapidly recognize and
eliminate systemically-administered Ad vectors from the bloodstream. However, pre-existing
immunity should also be taken into account when localized delivery into distal cancer sites or
metastases is anticipated. In the context of ovarian cancer applications, vector neutralization by nAbs
present in ascitic fluid may be circumvented by genetic or chemical masking of the viral capsid, the
fiber in particular. Blackwell and colleagues reported successful evasion of nAbs in ascites using a
tropism-modified Ad5 vector with an integrin-binding RGD motif insertion in the fiber knob [94]. Our
research has utilized a similar masking approach by genetically inserting short high affinity peptides
targeted to receptors over-expressed on various tumors into the Ad5 fiber knob HI loop [146].
In this study, an Ad5 vector with a 12-mer epidermal growth factor receptor (EGFR)-targeting
peptide insertion demonstrated up to 700-fold improved transduction in patient-derived primary
EOC cells (hCARhigh/EGFRhigh) and protection from pre-existing nAbs in the presence of 2.5% highly
neutralizing ascites as compared to the parent vector Ad5.Luc. Future vector design strategies will
focus on combination of pseudotyping with targeting peptide insertions within the main capsomers,
with the view of improved immune evasion and simultaneously enhanced tumor-targeting.
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2.3.2. Fiber Deknobbing
Another genetic fiber-modification strategy is “deknobbing”, the removal or replacement of
the fiber knob domain with artificial peptide structures. This technique has been utilized in the
context of tropism-modification and vector re-targeting into integrin-expressing cells [147]. The Ad5
vectors carried a deleted knob domain and the last 15 shaft repeats, and had a genetically inserted
external trimerization motif coupled with an integrin-targeting RGD motif. The authors report
impaired infectivity, observed as delayed viral spread in vitro, but successful vector transduction into
hCAR-deficient cells, as well as retained functional integrity of the fiber protein. Intriguingly, while
an anti-knob antibody was capable of hampering the infectivity of the wild type Ad5, the deknobbed
virus retained its infectivity in the presence of the antibody. The study warrants further investigation
and detailed assessment of its antigenicity and immunogenicity, and describes a potential vector
platform for further modification for gene therapy purposes.
Belousova and colleagues designed complex fiber chimeras combining an affibody targeting
human epidermal growth factor receptor type 2 (Her2), a major tumor marker [148]. The Her2-specific
affibody has a three-helix bundle domain Z derived from Staphylococcus protein A, thus replacing the
trimeric knob structure, fused to the carboxy-terminal fragment of the T4 phage fibritin protein. The
foldon domain of the fibritin (Fc11) is connected to the affibody with a flexible peptide linker, thus
enabling correct trimerization and receptor binding of this artificial fiber protein. The authors report
that the proteins were expressed at equal levels to Ad5, and fully functional virions were successfully
targeted to Her2-expressing cells, thus suggesting the feasibility of this strategy for cancer-targeting.
Another strategy has employed replacement of the Ad5 fiber knob domain with a small chain T
cell receptor (scTCR) that is specific to the melanoma-associated cancer-testis antigen MAGE-A1
presented by HLA-A1, coupled with an extrinsic trimerization motif (Ad5.R1-scTCR) [149]. This
OAd vector not only showed ablated native tropism, but was also capable of efficient killing
of MAGE-A1(+)/HLA-A1(+) melanoma cells in an epitope-specific manner, thus demonstrating
rigorous cell-specificity and potential applicability for treatment of melanoma.
2.4. Chemical Shielding
OAds have proved successful in selective killing of cancer cells whilst sparing normal cells
by being engineered to “hijack” the cancer cell‘s altered tumor-suppressive cellular machinery.
Releasing progeny virions that spread across adjacent tissue to amplify the Ad effect, local Ad
administration has proved successful in clinical trials [150]. H101 Ad has been approved for use
in China to treat head and neck cancer (for a review, see [151]), while systemic delivery of OAds
for solid and metastatic tumors has proved more of a challenge. A major limitation in a clinical
setting is the interaction of Ad with components of the blood including macrophages, DCs, platelets,
erythrocytes and KCs. In particular, interaction with FX results in reduced bio-distribution through
re-directed Ad vector tropism to the liver. The resulting hepatic toxicity limits the use of high doses of
OAd [152–154]. As described in detail earlier, activation of the host innate immune system in response
to Ad capsid proteins facilitates Ad clearance coupled with activation of humoral immunity by the
presence of pre-existing nAbs, significantly reducing vector efficacy. Another important limitation
is the dependence of Ad for cell entry via the native hCAR [15,20]. hCAR expression is frequently
down-regulated in many cancers [120,155], in particular advanced ovarian cancer [156–158], currently
limiting the use of OAd in this setting.
Technological advances to balance effective targeting of Ads to cancer cells whilst avoiding
reduced Ad bio-availability through immune activation in vivo are now emerging. A number of
strategies are being developed (for a review, see [7]). Nanotechnology represents a plethora of
gene delivery vehicles where the potential for drug (or Ad) delivery via nanoparticle encapsulation
or conjugation to nanoparticle carriers is possible (for an excellent review, see [159]). Chemical
shielding using a number of distinct carriers to bypass the negative effects of Ad delivery in vivo
has been extensively studied. Some investigators have utilized multiple strategies to optimize gene
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delivery and minimize immune surveillance. Chemical shielding by covalent linkage via amine
chemistry on the Ad capsid, aim at reducing hepatocyte tropism through evasion of binding with
blood components, in particular FX and nAbs, and extending serum half-life.
2.4.1. PEGylated Polymeric Carriers
First described by O‘Riordan and colleagues [160], chemical modification of Ad by
covalent attachment of polyethylene glycol (PEG) to hexon and fiber, has been shown
to reduce immunogenicity, prevent nAb binding, increase solubility and Ad serum
half-life. Chillón and colleagues shielded the negatively-charged Ad particles with cationic
GL-67/dioleoylphosphatidylethanolamine-PEG (GL-67/DOPE-PEG) and achieved improved cell
transduction and protection from nAbs in vitro [161]. Disappointingly, the vector was not protected
from immune attacks in vivo as it was efficiently neutralized when delivered into immunized
mice. Another study reports the conjugation of Ad5 with metoxypolyethylene glycol succinimidyl
propionate (MPEG-SPA), which resulted in 10-fold improved nAbs evasion but dramatically
decreased transgene expression as compared to the non-PEGylated virus, likely due to compromised
hCAR-binding [162]. The same authors successfully generated a 5-kDa PEGylated Ad5 that showed
reduced levels of nAb production with increased anti-tumor efficacy against metastatic lung cancer
in mice [163].
PEGylation of Ad can prevent FX interactions, thus reducing hepatotoxicity and facilitating
escape from phagocytic cells [164]. A negatively-charged, non-immunogenic molecule, PEG is
hydrophilic and thereby increases solubility in vivo (for a review, see [165]). However, the addition of
sufficient PEG to mask FX binding sites on the capsid can substantially reduce cellular transduction
efficiency due to the ensuing bulkiness of modified Ad and reduced access of Ad ligands for target cell
attachment. In an attempt to overcome this, Suzuki-Kouyama and colleagues engineered PEGylated
Ad vectors using an avidin-biotin interaction within the hexon [166]. This proved unsuccessful as
aggregation of Ad vectors due to the strong affinity of avidin for biotin reduced Ad cell transduction.
Subsequently the same group targeted the Ad hexon for PEGylation but exploited the high affinity of
FX interaction as a hexon-specific adaptor molecule [164]. PEG conjugation to lysine residues on FX
led to random PEGylation and resulted in replacement of PEG-FX with endogenous FX in vivo. They
suggest future studies should focus on creating site-specific PEGylation of FX.
Prill and colleagues demonstrated a chemical shielding approach that can be modified to either
target or de-target hepatocytes according to the size of the PEG moiety [167]. They generated a small
number of PEG polymers (750 Da in contrast to 10 kDa molecules) specifically directed to the HVR5
of the Ad hexon that significantly reduced hepatocyte transduction after i.v. delivery. However, it is
hypothesized that this approach may fail in those individuals that have nAbs against regions of the
capsid other than the HVRs [165]. Highlighting the complexities of targeted gene therapy, Doronin
and colleagues demonstrated that a systemically administered OAd showed reduced hepatocyte
transduction when conjugated with 20 kDa PEG in comparison to a 5 kDa PEGylated OAd when
hepatocyte transduction was observed after 24 h [168]. The authors propose that Ad hepatocyte
transduction can occur via the integrin pathway via the RGD penton base (hCAR-independent)—an
effect that was inhibited by the larger 20 kDa PEG. The level of tumor cell transduction was
similar in 20 kDa PEGylated Ad and un-PEGylated vector and both demonstrated efficacy by
tumor elimination.
2.4.2. Bio-Reducible (Cationic) Polymers
Polymer-based strategies, including the use of bio-reducible polymers, have been studied in
depth in the non-viral field (for a review, see [169]), with a number of applications adapted for
the Ad field. In the context of cancer gene therapy applications, coating the Ad5 particle with
an arginine-grafted bio-reducible polymer (ABP) significantly increased Ad cellular transduction
in both hCARlow and hCARhigh cells in vitro [170]. The cationic ABP-coated Ad complex exhibited
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a significantly reduced immune response as measured by macrophage-derived IL-6 release in
comparison to the (naked) control Ad, suggesting the use of hybrid vectors comprising both
viral and non-viral DNA as a promising gene therapy approach. The authors subsequently
hypothesized that the size of their Ad-ABP complex might be too large for efficient cellular uptake
and may cause off-target sequestration [171]. They subsequently produced a cationic polymer
(mPEG-PEI-g-Arg-S-S-Arg-g-PEI-mPEG (PPSA) containing both bio-reducible disulphide bonds and
functional arginine moieties that reduced cytotoxicity and enhanced cancer cell transduction both
in vitro and in vivo. More recently, coating of two OAds with 5-amine polymers conjugated with
3.4K PEG (OAd/M3.4kPN5LG) or 5K PEG (OAd/M5kPN5LG) showed the strongest killing effects
in cancer cells in comparison to OAds coated with biopolymer alone or naked Ad [172].
In an attempt to reduce potential immunogenicity due to residual linker groups left
at the amine attachment site after release of the polymer, Prill and colleagues constructed
a cysteine residue at HVR5 (AdHexCys) that allowed attachment of thiol-based groups
(allowing reversible and irreversible interactions) in addition to a synthetic shielding
poly-[N-(2-hydroxypropyl)-methacrylamide] (pHPMA) polymer [173]. Fisher and colleagues
constructed an Ad5 vector coated with the multivalent hydrophilic pHPMA, coupled with
re-targeting ligands for basic fibroblast growth factor receptor (FGFR) and vascular endothelial
growth factor receptor (VEFG) [174]. This vector not only exhibited improved protection from
nAbs, but also efficiently infected receptor-positive cells in vitro and xenografts in vivo. The
authors describe this method could be used for conjugation of a wide range of targeting molecules
including peptides [175] and biological effectors, in order to generate vectors with altered tropism
and immunogenicity.
Expanding the principles of multiple strategies for enhanced OAd delivery to cancer cells, Kim
and colleagues produced an OAd expressing short hairpin RNA against IL-8 (Ad-∆B7-U6shIL8) to
(measurably) reduce the immune response against this vector [176]. Using a new biodegradable
poly cystaminebisacrylamide-diaminohexane [poly (CBA-DAH)] (CD), low cytotoxicity and high
efficiency of cellular transduction was achieved. The construct was conjugated with a RGD motif in
the penton base to exploit αvβ3/5-mediated cell internalization and further conjugated to PEG500.
The authors demonstrate an enhanced integrin-dependent apoptotic effect in a cancer cell line
with the Ad/CD-PEG500-RGD, an effect independent of hCAR. Furthermore, this vector showed
suppression of IL-8 and VEGF expression.
2.4.3. Liposomes
Liposomes have been studied extensively for various therapeutic purposes, and have been
adopted in some studies related to OAd administration. Delivery of Ad using an emulsion containing
a cationic lipid 1,2-dioleoyl-3-trimethylammonium propane (DOTAP) enhanced delivery of Ad to
mouse and human cancer cell lines in comparison to DOTAP liposomes. However, Ads were most
efficiently transduced in an emulsion containing an oil Lipiodol with 5 KDa PEG [177], an example
of another gene delivery vehicle. This is termed lipid-polymer hybrid nanoparticles (LPNs) (for a
review, see [159]). Combining a polymer core encapsulating the Ad with a surrounding lipid layer
enveloping the polymer core (for biocompatibility) and an outer PEG (chemical shield) provides
an excellent gene delivery vehicle. Of particular note is the controlled release capabilities from the
polymer core, a function of potential interest for some gene therapy applications.
2.4.4. Mechanical Means of Ad Delivery into Tumors
Ad vector delivery may be enhanced by the innovative combination of mechanical particle
coating and focused ultrasound [178,179]. In a recent study, Mo and colleagues investigated
the properties of passive accumulation of Ad vector into tumor tissue generated by ultrasound
in vivo [180]. Using multi-PEGylated gold as a nanoparticle for Ad delivery, they report that the
increase in density of Ad associated with the addition of gold particles enhanced focused inertial
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cavitation by ultrasound in comparison to Ad alone or Ad-pHPMA. This approach also maintained
shielding properties. They produced a nanoparticle comprising an outer coating of 2-kDa PEG
attached to an Ad conjugated with 5-kDa PEG and gold. A disulphide bond between the Ad and
PEG-gold enabled dissolution of the complex in the reducing conditions of the cancer cell and
infection reactivation. Using a combination of gold labelling and focused ultrasound, the authors
were able to demonstrate increased tumor accumulation of viral particles from 0.1% (no gold, no
ultrasound) to 12% (gold labelled, focused ultrasound) of the injected dose in the tumor following i.v.
administration in mice [180]. This has a number of potential clinical advantages, not to mention the
ability to potentially control the level and timing of Ad delivery—a strategy that could potentially be
readily applied to OAds.
2.4.5. Bi-Specific Adapter Molecules
As an alternative approach to develop Ads with altered tropism, the incorporation of bi-specific
non-covalently linked adapter molecules to target Ads towards target-specific cellular receptors is
under investigation. Bi-specific adapter molecules comprise an anti-Ad-fiber antibody conjugated to
a target cell-specific peptide. Early studies conjugating an anti-fiber moieties to folate [181], FGF [182],
EGF [183–185] and endothelial receptors [186] have demonstrated the potential for this targeted
strategy to improve Ad transduction (for a more extensive review, see [145]).
The targeting moiety of bi-specific adapter molecules that are not integrated into the viral
genome are consequently lost during viral replication. In the context of OAds, this is a significant
limitation as targeting and oncolytic potential is reduced. To overcome this, van Beusechem and
colleagues constructed a CRAd that incorporated an expression cassette for a bi-specific adapter
molecule within the CRAd genome [184]. The bi-specific single-chain (scFv) antibody 425-S11 is
composed of the anti-EGFR (scFv 425) and anti-Ad fiber knob (scFv S11). The antibody directs Ad
tropism towards EGFR-positive cancer cells. After CRAd replication and oncolysis, newly released
virus and antibody bind and spread to neighboring cells in an EGFR-targeted (hCAR-negative)
manner. Carette and colleagues utilized the same CRAd but incorporated hCAR and integrin-binding
mutations to abolish native receptor binding in an attempt to implement a stricter targeting approach
(CRAd Ad∆24P*F*-425S11) [187]. The results demonstrated a significant increase in oncolysis in
hCAR-deficient, EGFR-positive cancer cells.
As an alternative to the antibody-based approach, more recent studies have developed targeted
strategies involving designed ankyrin repeat proteins (DARPins) that bind to the Ad5 fiber knob
(mutated to ablate hCAR-binding) and fused this protein with a DARPin specific for the tumor
marker Her2 [188,189]. This approach can be applied to a number of targeting strategies. The
adapter contains two fused molecules, both of which contain DARPins; one binding the Ad5 fiber
knob and the other with the capacity to bind to a range of cancer cell markers. Harvey and
colleagues have constructed two bi-specific peptides by fusing the extracellular domain of hCAR
with an EGFR- or urokinase-type plasminogen activator receptor (uPAR)-targeting polypeptide
in order to achieve retargeting of an Ad5-based vector (Ad-CMV-lacZ) into these major tumor
markers [190]. Co-administration of an Ad-CMV-lacZ vector with the fusion peptides resulted in
significantly improved targeting into EGFRhigh/hCARlow or uPARhigh/hCARlowovarian and bladder
cancer tissues, relative to control Ad5. Another bi-specific retargeting strategy has exploited the high
affinity interaction between the Ad5 hexon and the Gla domain of FX [25] by designing adapter
molecules consisting of the Gla domain fused to ScFvs with variable specificities [185]. In this study,
an Ad5 vector were successfully bridged into major tumor markers such as Her2, EGFR and the
stem cell marker ATP-binding cassette protein G2 (ABCG2) via the adapter molecules, suggesting the
potential for this strategy for bi-specific targeting purposes.
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3. Vector Design for Immuno-Oncolytic Therapies
3.1. Introduction
The persistent dilemma in Ad cancer immunotherapies remains—how to evade immune
recognition but to selectively stimulate cancer-specific immune responses. Cancer immunotherapy
is a current hot topic both in immunology and cancer research, and Ad-based vectors have
great promise within this area. The novel viral vector-based cancer immunotherapies commonly
utilize two main mechanisms for host immune activation: (A) immune priming or cancer
vaccination—lysis of infected tumor cells leading to innate immune responses and activation of
adaptive immune responses against the tumor-associated antigens (TAAs); and (B) localized release
of immunoregulatory agents that modulate signaling pathways defective in different cancer types
(reviewed in [191]). TAAs are derived from proteins synthesized by the tumor cell, and may
be either membrane-bound, secreted, cytoplasmic or localized in the nucleus [192]. Examples of
commonly studied TAAs for cancer gene therapy include CD19, CD20, CD30, CD40 CD33, CD52,
Her2, EGFR, VEGF, carcinoembryonic antigen (CEA), epithelial cell adhesion molecule (EpCAM)
(reviewed in [193]) and human MUC-1 (hMUC-1) [194]. Immuno-oncolytic Ad vectors can potentially
be used in combination with conventional chemo- and radiotherapies in order to target both primary
and metastatic tumors, and to achieve an enhanced and long-lasting therapeutic effect. Additionally,
they can be readily modified to carry “cargo” molecules—to express monoclonal antibodies (mAbs)
directed towards TAAs, T cell receptors, immune checkpoint inhibitors (such as anti-CTL4 and
anti-PD1), cytokines, and programmed to target DCs and tumor-infiltrating lymphocytes (TILs).
3.2. Cancer Vaccines
Ads are capable of infecting specific cell types in a receptor-dependent manner, and elicit
subtle innate and adaptive immune responses, which makes them feasible cancer vaccine vectors
for priming and stimulation of the host’s immune system (reviewed in [195]). Ads provide a number
of potential advantages as cancer vaccines over conventional therapies. They are tumor-selective, in
situ cancer vaccines, providing higher cancer-specificity and better safety margin. Additionally, they
are able to kill cancer cells through a range of mechanisms from direct virus-mediated cytotoxicity,
cell death due to anti-angiogenesis and vasculature targeting by Ads, to cytotoxic immune
effector-induced cytotoxicity. This induces cell death by apoptosis, necrosis, and autophagy [196].
With the exception of apoptosis, all other types of cell death have been considered to be inflammatory
and immunogenic. However, recent studies by investigators working on chemo- and radiotherapy
have led to new concepts, that apoptotic cell death can be divided into “immunogenic cell death”
(ICD) and “non-immunogenic cell death” [197,198]. Based on this new classification, apoptotic cell
death caused by some OAds are ICD. Together, immunogenic apoptosis, necrosis and autophagic cell
death caused by OAds provides a natural repertoire of TAAs in conjunction with danger signals
damage-associated molecular pattern (DAMP) and Ad-derived PAMPs, as well as inflammatory
cytokines [197]. Ideally, the strong elicited immune memory will then be able to recognize and
attack the tumor cells in the event of a relapse or development of metastatic tumors at any anatomical
location later in the patient’s life.
A number of viral vectors currently in clinical development have shown great promise for
amplification of the vaccinative effect of virus infection due to the insertion of the immunostimulatory
cytokine GM-CSF transgene into the viral genome [198–201]. Ad-based vectors have been engineered
to express TAAs such as Her2, tyrosinase-related protein 2 (TRP-2) and gp100 [202,203] that
are over-expressed in the tumor during infection, thus increasing the opportunity for immune
responses to be generated towards these tumor-specific antigens [204]. However, results suggest
that over-expression of a TAA is insufficient to overcome immunosuppression in the tumor or
immunodominant responses against viral antigens [205]. Therefore, additional approaches are
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required to boost TAA-specific responses. Priming the host with a heterologous vector expressing
the TAA prior to oncolytic vaccination significantly enhances the anti-tumoral response [205].
Previous studies demonstrate the potential of Ad5 to infect DCs via bridging interactions with
lactoferrin, produced locally at sites of inflammation, to DC-SIGN receptors on DCs in the absence of
hCAR expression [127]. This may limit the breath of immune stimulation as these cells are key actors
in immunoregulation and antigen presentation. To overcome this issue, a recent study describes
the generation of an Ad5-based vector with fiber knob pseudotyped with porcine Ad type 4 [206].
This chimaeric vector was shown to have improved transduction in DCs, improved tumor-specific
antigen presentation and T cell-mediated IFN-γ release in mice. Xie and colleagues describe the use
of a replication-deficient Ad expressing livin protein that is expressed on the surface of various cancer
cell types [207]. The vector exhibited improved DC transduction that led to cytotoxic T cell activation
against a panel of cancer cell lines in vitro.
Ad vectors have also been used as backbones for vaccines against HIV. The disappointing
results from the unsuccessful STEP trial have highlighted the potential limitations of Ad5 for vaccine
purposes, including for cancer applications, and therefore studies based on other serotypes appear
warranted [123]. In this study, Ad26, -35, and -48 vectors expressing lymphocytic choriomeningitis
virus (LCMV) glycoprotein, elicited high magnitude memory T cells, in addition to circumventing
high baseline Ad5-specific nAbs. While Ad5 vectors were able to elicit similarly high memory T cell
levels, they exhibited functional exhaustion and decreased anamnestic potential following secondary
antigen challenge. Therefore, the use of other serotypes than Ad5 warrants further investigation, and
may lead into the development of efficient and safe vector candidates in the future.
3.3. Immune Checkpoint Blockade
Immune checkpoint therapy, that targets regulatory pathways in T cells to enhance anti-tumor
immune responses, has led to important clinical advances and provided a new weapon in the war
against cancer [208]. The function of these pathways is to down-regulate T cell signaling in order to
prevent uncontrolled T cell proliferation, protecting tissues from auto-immune damage and maintain
tolerance to self-antigens. It is now clear that tumors co-opt certain immune-checkpoint pathways
as a major mechanism of immune resistance, particularly against T cells that are specific for tumor
antigens. [209]. Many of the immune checkpoints are controlled by ligand-receptor interactions,
which can be readily blocked by antibodies or modulated by recombinant forms of ligands or
receptors making them appealing therapeutic targets [210].
Antibodies targeting the immune inhibitory co-receptors cytotoxic T lymphocyte antigen 4
(CTLA-4) and programmed death-1 (PD-L1) have demonstrated clinical activity in a variety of tumor
types, including melanoma, RCC, and NSCLC [211,212] (reviewed in [213]). As novel anticancer
agents, they have a distinct profile of anti-tumor activity and toxicity, underscoring their unique
mechanism of activity. Whereas CTLA-4 and PD-1 both function as negative regulators, each plays a
non-redundant role in modulating immune responses [214]. CTLA-4 was the first immune checkpoint
receptor to be clinically targeted, and plays a pivotal role in attenuating the early activation of
naïve and memory T cells. Normally, after T cell activation, CTLA-4 is upregulated on the plasma
membrane where it functions to down-regulate T cell function by outcompeting the activating
receptor CD28, for its ligands, B7-1 (CD80) and B7-2 (CD86) [215]. In contrast, PD-1 is primarily
involved in modulating T cell activity in peripheral tissues via its interaction with its ligands PD-L1
and PD-L2. Unlike CTLA-4, PD-1 can be found on other activated lymphocytes including B cells
and NK cells. PD-L1 and PD-L2 are commonly upregulated on the surface of many different human
tumors. High expression levels of PD-L1 have been shown on melanoma, lung, ovarian, and other
human cancers [210,216].
The combination of Ads with a blockade of immune checkpoints is an exciting strategy that
may overcome current shortcomings associated with either approach alone. The Ad and the
immune-checkpoint blocker could be administered as two separate therapeutics but delivery of
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the checkpoint inhibitor directly from an Ad is a more appealing method. This would localize
the inhibitor to within the tumor microenvironment, conferring several advantages for both safety
and potency, and overcoming many of the adverse events observed with i.v. delivery. Given the
importance of the immune checkpoints in maintaining immune homeostasis there is concern that a
blockade of these receptors and/or ligands could lead to a break in immune self-tolerance, resulting
in autoimmune/autoinflammatory side effects. In the phase III trial of ipilimumab, Grade 3 or Grade
4 immune-related adverse events (including rash, colitis, hepatitis, and endocrinopathies) occurred in
10%–15% of patients treated with the anti-CTLA-4 antibody as compared to 3% of those treated with
gp100 alone. During this trial, there were 14 deaths related to ipilimumab (2.1%), 7 of which were
due to immune-related adverse events [217]. Delivering the immune-checkpoint from the oncolytic
virus would localize the treatment and may therefore mitigate the risks inherent in systemic delivery.
In preclinical studies of a replication-competent Ad expressing a full length CTLA-4 antibody
a 43-fold higher antibody concentration in the tumor as compared to the plasma was noted. The
plasma levels in treated mice remained below the reported human safety threshold [218]. Therefore,
viral delivery of anti-CTLA4 mAb led to increased tumor concentrations without increase in systemic
levels. In a separate study measles virus vectors encoding antibodies against CTLA-4 and PD-L1
showed therapeutic benefits in terms of delayed tumor progression and prolonged median overall
survival in animal studies [219], highlighting the important, synergistic potential that combining
immune checkpoint inhibition with an oncolytic viral activity may have within the future clinical
cancer arena.
4. Perspectives
Promising data arising from the OPTiM phase III clinical trial of T-VEC (previously known as
OncoVEX-GMCSF), demonstrate a durable and significantly increased response rate in patients with
malignant melanoma compared to controls [199,201]. This has helped to re-energize the field of
oncolytics, providing proof of concept in the technology, and demonstrating the clearest evidence
to date that virotherapies are finally coming of age in the clinical arena.
Within the new era of clinical virotherapies, technologies based on Ad are likely to be heavily
represented due to their ease of scale up, amenable genomes, long clinical history and potential
to achieve tumor-selectivity. In order to generate the most efficacious Ad-based delivery systems,
it is clear that a wide variety of considerations must be addressed. Firstly, capsid proteins must be
re-engineered and optimized to evade pre-existing immunity and other dose-limiting interactions
that promote uptake into a wide variety of non-target sites. Secondly, to ensure selectivity of
transduction, technologies must be adopted and developed to present tumor-selective targeting
ligands into the viral capsid, whilst “safety nets” must also be integrated into the viral genome
to ensure replication/transgene expression is unique to cancerous cells, for example, through the
inclusion of tumor-specific promoter elements or miRNA silencing elements within the viral genome.
Finally, the delivery of a suitable viral payload must be incorporated into the genomic armory,
whether a gene that directly or indirectly induces cell suicide in the tumor cells, or one that helps
to stimulate a suitable host anti-tumor immune response.
It is therefore clear that as our knowledge of Ad systems increases, so does the degree of
genetic re-engineering necessary to achieve efficient targeting increase. Therefore, the development
of successful Ad-based systems for cancer applications will necessitate a highly integrated approach,
and the use of high throughput systems for wholescale viral genome engineering, such as those
based on recombineering, to enable progression to clinics in a timelier manner than previously
considered possible.
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